![](/wp-content/uploads/2021/06/Oramed-ViaCyte-Dario-Announcement.png)
$599
ViaCyte Closes $45M Series D Tranche; Oramed Randomizes 50% of Patients in Oral Insulin Trial; Dario Completes wayForward Acquistion
A series of cardiometabolic news items have been observed: ViaCyte announced it has closed a $45M financing deal bringing the company’s Series D funding total to >$115M; Oramed announced it has enrolled and randomized 50% of the 675 T2DM patients in its Ph3 trial (ORA-D-013-1) evaluating its oral insulin; and Dario announced the closing of its acquisition of wayFoward. Below, FENIX provides highlights and insights for the respective news items.